Latest news
HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer - The ASCO PostThe ASCO Post · Thu, 06 Aug 2026 13:47:28 GMTDocirbrutinib Yields High Response Rates in MCL and CLL - OncLiveOncLive · Wed, 05 Aug 2026 15:26:11 GMTFrontline Zanubrutinib Plus Obinutuzumab Elicits Complete Responses in Older Patients With MCL - OncLiveOncLive · Mon, 03 Aug 2026 13:08:13 GMTBOND-003 Phase 3: Cretostimogene Shows 75% Complete Response Rate in BCG-Unresponsive NMIBC - OncodailyOncodaily · Sat, 01 Aug 2026 09:50:17 GMTCretostimogene Grenadenorepvec Shows Complete Responses in NMIBC - CancerNetworkCancerNetwork · Tue, 28 Jul 2026 17:08:36 GMT